Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

St Jude's Unify and Fortify CRM devices hit Japan

This article was originally published in Clinica

Executive Summary

St Jude Medical's Fortify ST implantable cardioverter defibrillator (ICD) and Unify cardiac resynchronisation therapy defibrillator (CRT-D) have been approved and launched in Japan. The devices, which St Paul, Minnesota firm claims are the smallest of their type, feature advanced battery technology and circuitry that allow for a smaller device, with more energy capacity, faster charge times, and increased longevity. The energy capacity of a device is particularly important for patients who have an enlarged heart, low ejection fraction, advanced heart failure or a high defibrillation threshold. They also incorporate a monitoring algorithm and technology designed to reduce inappropriate and unnecessary shocks. Unify and Fortify gained US premarket approval (PMA) last May (www.clinica.co.uk, 14 May 2010).

You may also be interested in...



Normality Reasserts Itself For Biotech IPOs

The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.

MRM Health Pulls A Pouchitis Hit Out Of The Bag

The mid-stage success is encouraging, but taking on Takeda won’t be easy.

Novartis Draws Out Its APPLAUSE

Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT097493

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel